338
Participants
Start Date
May 20, 2021
Primary Completion Date
May 16, 2022
Study Completion Date
November 22, 2022
LY3437943
Administered SC
Placebo
Administered SC
Allegheny Endocrinology Associates, Pittsburgh
East Coast Institute for Research, LLC, Jacksonville
Encore Medical Research - Weston, Weston
Suncoast Clinical Research, Inc., New Port Richey
New Phase Research and Development, Knoxville
Springfield Diabetes & Endocrine Center, Springfield
StudyMetrix Research, City of Saint Peters
Cotton O'Neil Diabetes and Endocrinology Center, Topeka
Tandem Clinical Research,LLC, Marrero
Intend Research, LLC, Norman
Southern Endocrinology Associates, Mesquite
Dallas Diabetes Research Center, Dallas
Juno Research, Houston
Endocrine Ips, Pllc, Houston
Texas Diabetes & Endocrinology, P.A., Austin
Perseverance Research Center, Scottsdale
Velocity Clinical Research, Huntington Park, Los Angeles
Velocity Clinical Research, Huntington Park, Huntington Park
Southern California Dermatology, Inc., Santa Ana
Anaheim Clinical Trials, LLC, Anaheim
Coastal Metabolic Research Centre, Ventura
Valley Research, Fresno
Diablo Clinical Research, Inc., Walnut Creek
Rainier Clinical Research Center, Renton
Amici Clinical Research LLC, Raritan
Private Practice - Dr. Paola Mansilla-Letelier, Guaynabo
GCM Medical Group, PSC - Hato Rey Site, San Juan
San Juan City Hospital, San Juan
Eli Lilly and Company
INDUSTRY